Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 358

1.

The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.

Berk T, Silberstein SD.

Headache. 2018 Mar 14. doi: 10.1111/head.13298. [Epub ahead of print]

PMID:
29536530
2.

A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study).

Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW.

Cephalalgia. 2018 Jan 1:333102418762525. doi: 10.1177/0333102418762525. [Epub ahead of print]

PMID:
29504483
3.

Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.

Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ; International Headache Society Clinical Trials Standing Committee.

Cephalalgia. 2018 Apr;38(5):815-832. doi: 10.1177/0333102418758283. Epub 2018 Mar 4.

PMID:
29504482
4.

Preventive Therapies for Chronic Migraine.

Silberstein SD, Yeung PP, Aycardi E.

N Engl J Med. 2018 Feb 22;378(8):774. doi: 10.1056/NEJMc1716990. No abstract available.

5.

Current management: migraine headache.

Silberstein SD.

CNS Spectr. 2017 Dec;22(S1):1-13. doi: 10.1017/S1092852917000864.

PMID:
29350125
6.

Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial.

Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC.

J Am Coll Cardiol. 2017 Dec 5;70(22):2766-2774. doi: 10.1016/j.jacc.2017.09.1105.

PMID:
29191325
7.

Fremanezumab for the Preventive Treatment of Chronic Migraine.

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E.

N Engl J Med. 2017 Nov 30;377(22):2113-2122. doi: 10.1056/NEJMoa1709038.

PMID:
29171818
8.

The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations.

Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ.

Am J Manag Care. 2017 Nov;23(17 Suppl):S326-S333.

9.

CGRP Monoclonal Antibodies for Migraine: Rationale and Progress.

Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD.

BioDrugs. 2017 Dec;31(6):487-501. doi: 10.1007/s40259-017-0250-5.

PMID:
29116598
10.

AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial.

Lipton RB, McGinley JS, Shulman KJ, Silberstein SD, Wirth RJ, Buse DC.

Headache. 2018 Feb;58(2):229-242. doi: 10.1111/head.13199. Epub 2017 Oct 16.

PMID:
29034453
11.

A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.

Silberstein SD.

Expert Opin Drug Saf. 2018 Jan;17(1):89-97. doi: 10.1080/14740338.2018.1390563. Epub 2017 Oct 20. Review.

PMID:
28994319
12.

Histamine and Migraine.

Yuan H, Silberstein SD.

Headache. 2018 Jan;58(1):184-193. doi: 10.1111/head.13164. Epub 2017 Sep 1.

PMID:
28862769
13.

Neuropeptides.

Silberstein SD.

Headache. 2017 May;57 Suppl 2:35-36. doi: 10.1111/head.13093. No abstract available.

PMID:
28485847
14.

Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes.

Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ.

Headache. 2017 May;57(5):766-777. doi: 10.1111/head.13074. Epub 2017 Apr 6.

15.

Topiramate in Migraine Prevention: A 2016 Perspective.

Silberstein SD.

Headache. 2017 Jan;57(1):165-178. doi: 10.1111/head.12997. Epub 2016 Nov 30. Review.

PMID:
27902848
16.

Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study.

Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ; ACT1 Study Group.

Headache. 2016 Sep;56(8):1317-32. doi: 10.1111/head.12896.

17.

The American Headache Society Cluster Guidelines.

Silberstein SD.

Headache. 2016 Jul;56(7):1091-2. doi: 10.1111/head.12867. No abstract available.

PMID:
27432622
18.

Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.

Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR; EVENT Study Group.

Neurology. 2016 Aug 2;87(5):529-38. doi: 10.1212/WNL.0000000000002918. Epub 2016 Jul 13.

19.

The migraine postdrome: An electronic diary study.

Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ.

Neurology. 2016 Jul 19;87(3):309-13. doi: 10.1212/WNL.0000000000002789. Epub 2016 Jun 22.

20.

Considerations for management of migraine symptoms in the primary care setting.

Silberstein SD.

Postgrad Med. 2016 Jun;128(5):523-37. doi: 10.1080/00325481.2016.1175912. Epub 2016 May 10. Review.

PMID:
27078039
21.

Erratum to: Targeting CGRP: A New Era for Migraine Treatment.

Wrobel Goldberg S, Silberstein SD.

CNS Drugs. 2016 Apr;30(4):355. No abstract available.

PMID:
27067342
22.

The Use of Botulinum Toxin in the Management of Headache Disorders.

Silberstein SD.

Semin Neurol. 2016 Feb;36(1):92-8. doi: 10.1055/s-0036-1571443. Epub 2016 Feb 11.

PMID:
26866501
23.

Long-Term Pain Reduction Does Not Imply Improved Functional Outcome in Patients Treated With Combined Supraorbital and Occipital Nerve Stimulation for Chronic Migraine.

Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, Young WB, Silberstein SD, Sharan AD.

Neuromodulation. 2016 Jul;19(5):507-14. doi: 10.1111/ner.12400. Epub 2016 Feb 10.

PMID:
26861893
24.

Single-item migraine screening tests, self-reported bothersome headache or stripe pattern hypersensitivity?

Yuan H, Hopkins M, Goldberg JD, Silberstein SD.

Acta Neurol Scand. 2016 Oct;134(4):277-83. doi: 10.1111/ane.12539. Epub 2015 Dec 1.

PMID:
26626126
25.

Vagus Nerve Stimulation and Headache.

Yuan H, Silberstein SD.

Headache. 2017 Apr;57 Suppl 1:29-33. doi: 10.1111/head.12721. Epub 2015 Oct 16. Review.

PMID:
26473407
26.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB.

Lancet Neurol. 2015 Nov;14(11):1081-90. doi: 10.1016/S1474-4422(15)00249-5. Epub 2015 Sep 30.

PMID:
26432182
27.

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD.

Lancet Neurol. 2015 Nov;14(11):1091-100. doi: 10.1016/S1474-4422(15)00245-8. Epub 2015 Sep 30.

PMID:
26432181
28.

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part II.

Yuan H, Silberstein SD.

Headache. 2016 Feb;56(2):259-66. doi: 10.1111/head.12650. Epub 2015 Sep 18. Review.

PMID:
26381725
29.

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part III.

Yuan H, Silberstein SD.

Headache. 2016 Mar;56(3):479-90. doi: 10.1111/head.12649. Epub 2015 Sep 14. Review.

PMID:
26364805
30.

Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part I.

Yuan H, Silberstein SD.

Headache. 2016 Jan;56(1):71-8. doi: 10.1111/head.12647. Epub 2015 Sep 14. Review.

PMID:
26364692
31.

Preventive Migraine Treatment.

Silberstein SD.

Continuum (Minneap Minn). 2015 Aug;21(4 Headache):973-89. doi: 10.1212/CON.0000000000000199. Review.

32.

Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial.

Bigal ME, Lipton RB, Newman LC, Pierce MW, Silberstein SD.

Headache. 2015 Sep;55(8):1124-32. doi: 10.1111/head.12606. Epub 2015 Jul 14. Erratum in: Headache. 2015 Nov;55(10):1479.

PMID:
26178815
33.

Targeting CGRP: A New Era for Migraine Treatment.

Wrobel Goldberg S, Silberstein SD.

CNS Drugs. 2015 Jun;29(6):443-52. doi: 10.1007/s40263-015-0253-z. Review. Erratum in: CNS Drugs. 2016 Apr;30(4):355.

PMID:
26138383
34.

Efficacy and Tolerability of STOPAIN for a Migraine Attack.

St Cyr A, Chen A, Bradley KC, Yuan H, Silberstein SD, Young WB.

Front Neurol. 2015 Feb 4;6:11. doi: 10.3389/fneur.2015.00011. eCollection 2015.

35.

Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.

Lipton RB, Silberstein SD.

Headache. 2015 Mar;55 Suppl 2:103-22; quiz 123-6. doi: 10.1111/head.12505_2. Review.

PMID:
25662743
36.

The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.

Marmura MJ, Silberstein SD, Schwedt TJ.

Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Review.

PMID:
25600718
37.

Acute migraine treatment.

Silberstein SD, Marmura MJ.

Headache. 2015 Jan;55(1):1-2. doi: 10.1111/head.12504. No abstract available.

PMID:
25600717
38.

Does migraine produce facial palsy? For whom the Bell tolls.

Silberstein SD, Silvestrini M.

Neurology. 2015 Jan 13;84(2):108-9. doi: 10.1212/WNL.0000000000001136. Epub 2014 Dec 17. No abstract available.

PMID:
25520314
39.

Late-life migraine accompaniments: A narrative review.

Vongvaivanich K, Lertakyamanee P, Silberstein SD, Dodick DW.

Cephalalgia. 2015 Sep;35(10):894-911. doi: 10.1177/0333102414560635. Epub 2014 Dec 12. Review.

PMID:
25505036
40.

Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.

Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.

J Neurol Neurosurg Psychiatry. 2015 Sep;86(9):996-1001. doi: 10.1136/jnnp-2013-307149. Epub 2014 Dec 12.

41.

Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.

Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.

J Pain. 2015 Feb;16(2):164-75. doi: 10.1016/j.jpain.2014.11.004. Epub 2014 Nov 15.

PMID:
25464159
42.

Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J; ALD403 study investigators.

Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5.

PMID:
25297013
43.

TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp.

Silberstein SD.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):361. doi: 10.1136/jnnp-2014-309295. Epub 2014 Oct 6. No abstract available.

PMID:
25288609
44.

Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management.

Dougherty C, Silberstein SD.

Pain Pract. 2015 Sep;15(7):688-92. doi: 10.1111/papr.12243. Epub 2014 Oct 1. Review.

PMID:
25271173
45.

Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: long-term results from a randomized, multicenter, double-blinded, controlled study.

Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, Sharan AD, Narouze S, Mogilner AY, Trentman TL, Ordia J, Vaisman J, Goldstein J, Mekhail N.

Cephalalgia. 2015 Apr;35(4):344-58. doi: 10.1177/0333102414543331. Epub 2014 Jul 30.

PMID:
25078718
46.

COX inhibitors for the treatment of migraine.

Silberstein SD, Stirpe JC.

Expert Opin Pharmacother. 2014 Sep;15(13):1863-74. doi: 10.1517/14656566.2014.937704. Epub 2014 Jul 10. Review.

PMID:
25010639
47.

Operational diagnostic criteria for chronic migraine: expert opinion.

Silberstein SD, Lipton RB, Dodick DW.

Headache. 2014 Jul-Aug;54(7):1258-66. doi: 10.1111/head.12407. Epub 2014 Jul 2. Review.

PMID:
24990187
48.

Headaches caused by nasal and paranasal sinus disease.

Marmura MJ, Silberstein SD.

Neurol Clin. 2014 May;32(2):507-23. doi: 10.1016/j.ncl.2013.11.001. Epub 2014 Feb 26. Review.

PMID:
24703542
49.

Is the migraine brain super-active?

Silberstein SD.

Pain. 2014 Jun;155(6):1049-50. doi: 10.1016/j.pain.2014.03.002. Epub 2014 Mar 13. No abstract available.

PMID:
24631595
50.

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.

Acta Neurol Scand. 2014 Jan;129(1):61-70. doi: 10.1111/ane.12171. Epub 2013 Sep 20.

Supplemental Content

Loading ...
Support Center